Daewoong wins patent suit against CTCBIO
The company announced on December 28 that it secured the right to sell its new anti-urinary incontinence medication on Korean market after the Korean Intellectual Property Tribunal ruled that CTCBIO’s patent lacks a novelty and...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
